Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nintedanib Formulations in Healthy Males
NCT05262751Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Area Under the Concentration-time Curve From 0 Extrapolated to Infinity. Started Mar 2022; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05262751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262751.